FDA Rare Disease Framework Puts CMC Review in Scope
The FDA’s Rare Disease Framework Initiative brings risk-based CMC review and pre-approval inspections into scope for sponsors, CDMOs, and quality teams.
Read the full report on Pharmtech
Story file
How this page works. The Headline Update lists this report from Pharmtech with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.
